| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | NEUTRAL | BUY | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.40▼ | 1.40▼ | 1.41▼ | 1.33▲ | 1.28▲ |
| MA10 | 1.41▼ | 1.40▼ | 1.39▼ | 1.23▲ | 1.45▼ |
| MA20 | 1.41▼ | 1.39▼ | 1.38▼ | 1.29▲ | 1.59▼ |
| MA50 | 1.39▼ | 1.33▲ | 1.26▲ | 1.41▼ | 2.04▼ |
| MA100 | 1.33▲ | 1.26▲ | 1.30▲ | 1.60▼ | 4.05▼ |
| MA200 | 1.28▲ | 1.33▲ | 1.36▲ | 1.76▼ | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.004▼ | -0.004▼ | -0.004▼ | 0.025▲ | N/A |
| RSI | 38.676▼ | 49.896▼ | 54.837▲ | 53.330▲ | N/A |
| STOCH | 75.000 | 78.205 | 79.744 | 49.365 | 15.254▼ |
| WILL %R | -100.000▼ | -61.538 | -66.667 | -37.500 | -76.378▼ |
| CCI | -202.155▼ | -35.619 | 6.349 | 86.999 | -64.531 |
|
Friday, September 11, 2020 06:56 AM
Before it's here, it's on the Bloomberg Terminal.
|
|
Tuesday, September 08, 2020 01:51 PM
(ALNA -1.3%) has dosed the first patient in a Phase 1 trial of ALLN-346, for the treatment of hyperuricemia (elevated levels of uric acid in the blood) in patients with gout and advanced chronic ...
|
|
Thursday, September 03, 2020 09:00 AM
Sept. 03, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 18/09/20 | 1.37 | 1.43 | 1.34 | 1.37 | 730,089 |
| 17/09/20 | 1.33 | 1.4296 | 1.32 | 1.37 | 418,499 |
| 16/09/20 | 1.33 | 1.43 | 1.22 | 1.38 | 1,274,968 |
| 15/09/20 | 1.24 | 1.55 | 1.21 | 1.31 | 1,988,900 |
| 14/09/20 | 1.14 | 1.2399 | 1.08 | 1.21 | 1,091,644 |
| 11/09/20 | 1.15 | 1.15 | 1.07 | 1.10 | 687,385 |
| 10/09/20 | 1.17 | 1.2201 | 1.12 | 1.12 | 803,857 |
| 09/09/20 | 1.17 | 1.19 | 1.1601 | 1.17 | 522,487 |
| 08/09/20 | 1.18 | 1.21 | 1.14 | 1.145 | 647,161 |
| 04/09/20 | 1.27 | 1.32 | 1.11 | 1.16 | 1,468,280 |
|
|
||||
|
|
||||
|
|